U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482813) titled 'An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa' on March 04.
Brief Summary: The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.
Study Start Date: July 15, 2026
Study Type: INTERVENTIONAL
Condition:
Epidermolysis Bullosa (EB)
Intervention:
DRUG: SD-101 Dermal Cream (6%)
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and o...